Cargando…

Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review

BACKGROUND: A large proportion of patients eventually experience disease progression despite treatment with immune checkpoint inhibitors (ICIs), but subsequent treatment options are limited for this population. Retreatment with the same or different types of ICIs is a possible strategy, but the clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Kaili, Li, Jiarui, Sun, Zhao, Zhao, Lin, Bai, Chunmei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705192/ https://www.ncbi.nlm.nih.gov/pubmed/33294036 http://dx.doi.org/10.1177/1758835920975353

Ejemplares similares

Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review
por: Li, Jiarui, et al.
Publicado: (2020)

The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
por: Perdyan, Adrian, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis
por: Yang, Kaili, et al.
Publicado: (2020)

Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review
por: Xu, Ling-Yi, et al.
Publicado: (2023)

Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Zhao, Mei, et al.
Publicado: (2023)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review
por: Shalata, Walid, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes
por: Shek, Dmitrii, et al.
Publicado: (2021)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer
por: Palma dos Reis, Ana Filipa, et al.
Publicado: (2022)

The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis
por: Chang, Yu, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors against Advanced or Metastatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
por: Park, Eun-Joo, et al.
Publicado: (2022)

Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review
por: Guo, Yusheng, et al.
Publicado: (2022)

Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis
por: Cai, Zijing, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists’ Perspectives
por: Farshidpour, Maham, et al.
Publicado: (2022)

Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials
por: Poulose, Jissy Vijo, et al.
Publicado: (2022)

Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
por: Trontzas, Ioannis P., et al.
Publicado: (2023)

Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System
por: Xing, Jiazhang, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review
por: Al-Showbaki, Laith, et al.
Publicado: (2023)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review
por: Mearns, Elizabeth S, et al.
Publicado: (2018)

Increasing cure rates of solid tumors by immune checkpoint inhibitors
por: Ma, Weijie, et al.
Publicado: (2023)

Comparison of Endodontic Failures between Nonsurgical Retreatment and Endodontic Surgery: Systematic Review and Meta-Analysis with Trial Sequential Analysis
por: Dioguardi, Mario, et al.
Publicado: (2022)

Immune checkpoint inhibitor‐induced Type 1 diabetes: a systematic review and meta‐analysis
por: Akturk, H. K., et al.
Publicado: (2019)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis
por: Su, Qiang, et al.
Publicado: (2019)

Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis
por: Wei, Wei, et al.
Publicado: (2020)

Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
por: Castellano, Daniel, et al.
Publicado: (2022)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
por: Liu, Qingxu, et al.
Publicado: (2023)

Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors
por: Chen, Yu, et al.
Publicado: (2020)

Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors
por: Ahn, Ryuhjin, et al.
Publicado: (2021)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Chan, Daisy Wai-Ka, et al.
Publicado: (2022)

A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines
por: Donkor, Kofi N, et al.
Publicado: (2023)

Inhibiting the inhibitors: Checkpoints blockade in solid tumors
por: Mavilio, Domenico, et al.
Publicado: (2013)

The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors
por: Koustas, Evangelos, et al.
Publicado: (2020)

Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis
por: Zhao, Zhe, et al.
Publicado: (2023)

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jtv9mvs016j34de7buonlio3ms